Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth
- 2 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 39 (41), 6480-6492
- https://doi.org/10.1038/s41388-020-01444-3
Abstract
Angiogenesis inhibitors, such as the receptor tyrosine kinase (RTK) inhibitor sunitinib, target vascular endothelial growth factor (VEGF) signaling in cancers. However, only a fraction of patients respond, and most ultimately develop resistance to current angiogenesis inhibitor therapies. Activity of alternative pro-angiogenic growth factors, acting via RTK or G-protein coupled receptors (GPCR), may mediate VEGF inhibitor resistance. The phosphoinositide 3-kinase (PI3K)β isoform is uniquely coupled to both RTK and GPCRs. We investigated the role of endothelial cell (EC) PI3Kβ in tumor angiogenesis. Pro-angiogenic GPCR ligands were expressed by patient-derived renal cell carcinomas (PD-RCC), and selective inactivation of PI3Kβ reduced PD-RCC-stimulated EC spheroid sprouting. EC-specific PI3Kβ knockout (ΕC-βKO) in mice potentiated the sunitinib-induced reduction in subcutaneous growth of LLC1 and B16F10, and lung metastasis of B16F10 tumors. Compared to single-agent sunitinib treatment, tumors in sunitinib-treated ΕC-βKO mice showed a marked decrease in microvessel density, and reduced new vessel formation. The fraction of perfused mature tumor microvessels was increased in ΕC-βKO mice suggesting immature microvessels were most sensitive to combined sunitinib and PI3Kβ inactivation. Taken together, EC PI3Kβ inactivation with sunitinib inhibition reduces microvessel turnover and decreases heterogeneity of the tumor microenvironment, hence PI3Kβ inhibition may be a useful adjuvant antiangiogenesis therapy with sunitinib.This publication has 55 references indexed in Scilit:
- Antiangiogenic Agent Sunitinib Transiently Increases Tumor Oxygenation and Suppresses Cycling HypoxiaCancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Endogenous regulation of cardiovascular function by apelin-APJAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesisNature, 2008
- Class I PI3K in oncogenic cellular transformationOncogene, 2008
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacyProceedings of the National Academy of Sciences of the United States of America, 2007
- Genes that Distinguish Physiological and Pathological AngiogenesisCancer Cell, 2007
- Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycinCancer Cell, 2006
- The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tractNature, 1998